哌柏西利治疗失败的晚期乳腺癌患者后续治疗生存获益分析
Analysis of survival benefits in subsequent treatment for patients with advanced breast cancer after failure of palbociclib therapy
李敏 1史业辉1
作者信息
- 1. 天津医科大学肿瘤医院乳腺肿瘤内科, 国家恶性肿瘤临床医学研究中心, 天津市"肿瘤防治"重点实验室, 天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室(天津市 300060)
- 折叠
摘要
目的:探讨哌柏西利治疗失败后HR+/HER-转移性乳腺癌(metastatic breast cancer,MBC)患者使用化疗或内分泌±靶向治疗生存时间及预后因素.方法:回顾性收集 2018年 8月至 2022年 12月于天津医科大学肿瘤医院接受哌柏西利治疗但发生进展的 133例晚期乳腺癌患者的临床资料、随访无进展生存时间(progression-free survival,PFS)及总生存时间(overall survival,OS).结果:72.2%患者接受哌柏西利治疗前曾行解救化疗,66.2%患者在解救治疗三线及以后使用哌柏西利,67.7%患者哌柏西利进展后接受化疗,69.2%患者哌柏西利进展时远处转移器官数目多于 3个.内分泌±靶向治疗组和化疗组患者的中位PFS分别为 3.2个月和 4.9个月(P=0.017);中位OS分别为 18.2个月和 21.5个月,差异具有统计学意义(P=0.019).多因素分析结果未见影响PFS及OS的独立危险因素.结论:真实世界中多数HR+/HER-MBC患者在哌柏西利进展后选择化疗作为解救治疗方案,但内分泌±靶向治疗的PFS、OS长于化疗组.
Abstract
Objective:To explored the survival benefit and prognostic factors of patients receiving chemotherapy or endocrine±targeted therapy after palbociclib treatment in patients with HR+/HER2-metastatic breast cancer(HR+/HER2-MBC).Methods:We identified patients who had been diagnosed with HR+/HER2-MBC and had received palbociclib-based therapy at Tianjin Medical University Cancer Institute&Hospital between August 2018 and December 2022.Clinical information,progression-free survival(PFS),and overall survival(OS)of patients on palbociclib treatments were collected from medical records and outpatient facilities.Results:72.2%of patients were treated with rescue chemotherapy prior to palbociclib,66.2%received palbociclib≥3 lines at baseline in MBC setting,67.7%were treated with chemotherapy after progression on palbociclib,and 69.2%had≥3 metastatic organs.Differences were observed between chemotherapy group versus en-docrine±targeted therapy in PFS(3.2 months vs.4.9 months;P=0.017)and OS(18.2 months vs.21.5 months;P=0.019).Multivariate analysis found no independent prognostic factors that affected PFS or OS.Conclusions:Chemotherapy is the first choice for most patients with HR+/HER2-MBC after palbociclib treatment failure;however,PFS and OS are longer in patients receiving endocrine±targeted therapy than in those receiving chemotherapy.
关键词
HR+/HER2-转移性乳腺癌/哌柏西利/进展/预后Key words
HR+/HER2-metastastic breast cancer(HR+/HER2-MBC)/palbociclib/progression/prognosis引用本文复制引用
出版年
2024
NETL
NSTL
万方数据